Read Dr. Louise Moyle’s Early Career Blog
Read the latest early career blog post, from NMD4C member Dr. Louise Moyle.
Dr. Louise Moyle is a postdoctoral fellow at the Institute of Biomedical Engineering at the University of Toronto, Canada. Her research investigates mechanisms of muscle stem cell dysfunction in neuromuscular disorders, with the aim of transferring this knowledge towards future cell and gene therapies. She completed her PhD in Dr. Peter Zammit’s lab at King’s College London (UK), where she investigated muscle stem cell regeneration in facioscapulohumeral muscular dystrophy (FSHD). She is currently working in the laboratory of Dr. Penney Gilbert, where she is supported by a Medicine by Design postdoctoral fellowship. This research aims to understand how mechanosensing via the LINC complex contributes to the process muscle stem cell repair, with relevance to Emery-Dreifuss muscular dystrophy.
Read next...
NMD4C Hosts 3rd Annual Basic Research Summer School at uOttawa!
From June 8 to 10, 2026, we hosted the 3rd annual NMD4C Basic Research Summer School at the University of Ottawa. The program supported 28 neuromuscular research trainees (graduate students and postdoctoral fellows) from across Canada and focused on developing practical skills, strengthening core knowledge in neuromuscular research, and providing opportunities to present and discuss their work. Through a combination of tutorials, lectures, hands-on workshops in cutting-edge wet lab techniques, flash talks, and both structured and informal networking, participants engaged with faculty, exchanged ideas, and built connections across institutions and career stages.
New Publication from the NMD4C Clinical Trial Network Strengthens Trial Capacity in Canada
We are pleased to share a new publication from the NMD4C Clinical Trial Network led by Kerri Lynn Schellenberg, Homira Osman, Maria Masnata, Rhiannon Hicks, Corinne Kagan, Ana Stosic, Stacey Lintern, Erin Beattie, Drs. Hanns Lochmüller, Craig Campbell, and Jean K Mah. This work focuses on the implementation of a coordinated Canadian neuromuscular clinical trial network to enhance trial readiness, capacity, and access in rare disease research.
Canadian-Led Phase II Studies Advance Vamorolone Evidence in Duchenne Muscular Dystrophy
NMD4C investigators contributed to two phase II studies evaluating vamorolone in boys with Duchenne muscular dystrophy across early childhood and adolescence, demonstrating safety, favorable pharmacokinetics, and potential efficacy. Led by Dr. Jean Mah and conducted across Canadian clinical trial sites with national and industry collaborators, the findings supported Health Canada approval of vamorolone as the first treatment for DMD in Canada. Leaders from both the clinical and patient advocacy communities, including Defeat Duchenne Canada, highlighted the impact of collaboration among patients, families, clinicians, and researchers in advancing care and improving access to new therapies.